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Abstract
Background: MicroRNAs have recently been introduced as epigenetic regulators of glucose and lipid metabolic pathways, which
are impaired in obesity and diabetes.
Objectives: We evaluated the effects of calorie-restricted diet therapy on the circulating levels of miR-33b and miR-29a in relation-
ship to glucose and lipid metabolic parameters in obese patients with type 2 diabetes mellitus (T2DM).
Methods: This randomized clinical controlled trial was performed on 30 eligible obese women with T2DM, randomly divided into
two groups (control group, n = 15; diet therapy group, n = 15) for 10 weeks. Ten healthy women with normal weight were enrolled at
the baseline of the study as controls. Demographic information, dietary intake, and anthropometric and biochemical indices were
obtained before and after the study. Circulating miR-33b and miR-29a were assessed for all subjects using quantitative RT-PCR, and
the fold change of each circulating miRNA was compared between groups.
Results: The circulating levels of miR-29a and miR-33b in the diabetic women were higher (0.40-fold) and lower (1.43-fold), respec-
tively, than normal levels. Diet therapy significantly increased the circulating level of miR-33b (P = 0.023, 0.97-fold upregulation) to
normal levels. This increase was independently correlated with caloric restriction (95%CI: -0.004 to -0.0001, P = 0.022) and 2hPPBS
(95%CI: -0.009 to -0.001, P = 0.035). No remarkable change was observed in circulating levels of miR-29a.
Conclusions: Our findings introduced a novel therapeutic effect of diet therapy on circulating miRNAs in obese patients with T2DM.
MiR-33b is an important therapeutic target in the treatment and prevention of T2DM and its complications.
Keywords: Diet Therapy, microRNAs, Diabetes, Obesity
1. Background
Global estimates have reported an increasing inci-
dence of type 2 diabetes mellitus (T2DM) over the past 15
years. T2DM and its debilitating micro- and macrovascu-
lar complications have profound effects on public health
(1). It is a complex disorder resulting from interactions
between genes and environmental factors, including obe-
sity and dietary intake (2). Obesity (defined as a body mass
index [BMI] of ≥ 30 kg/m2) contributes to approximately
half of the worldwide incidence of T2DM (3). Compared
to the global incidence of T2DM (~ 13% of adults) in 2014,
the rate in Iran was 26.3% in 2008 (4). The American dia-
betes association (ADA) has reported that nutritional fac-
tors play a critical role in the prevention and management
of obesity and its related metabolic complications (5). Nu-
tritional factors and a positive caloric balance can affect a
variety of obesity- and diabetes-related epigenetic factors
(6, 7). Interactions between nutrition, obesity, and gene ex-
pression may cause the higher incidence of T2DM among
families and its more progressive pathology in the Middle
East, including Iran, compared to other countries (8).
MicroRNA (miRNA), a key post-translational regulator
of gene expression, is a class of non-coding small RNA (~ 22
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nucleotides) (9) that inhibits mRNA translation by target-
ing the 3′ un-translational region (3’UTR) (10). MiRNAs sta-
bly exist in bodily fluids such as blood; they are disease-
specific and their circulating levels reflect their expres-
sion patterns (11). Under healthy conditions, miRNAs reg-
ulate the expression of cognate target genes, but under
unhealthy conditions, such as obesity, any disturbance in
the expression of individual miRNAs can cause the dys-
regulated expression of target genes and disease-specific
complications (12). The dysregulated circulating levels of
miR-33b and miR-29a have recently been introduced as
metabolic-disease-specific biomarkers in obese patients.
MiR-33a and b are located within the introns of the sterol
regulatory element-binding protein (SREBP), respectively
SREBP-2 and SREBP-1c. This family is the key regulator of
glucose homeostasis via targeting numerous related genes
(13-15). Several studies have identified the regulatory roles
of the miR-29 family (a, b, and c) in glucose metabolism and
insulin signaling (15-17). The over-expression of miR-29a re-
duces insulin-dependent glucose uptake, reduces cellular
and hepatic glucose production (16, 18), and suppresses the
expression of Syntaxin 1A (Stx1a), a key regulatory gene of
insulin synaptic exocytose from the β-cells (16).
The most recent evidence suggests the potential of
miR-33b and miR-29a as targets for the early diagnosis
and treatment of glucose homeostasis disruptions and the
complications of T2DM (19). MiR-33b is encoded in humans
and other large mammals (13, 20), but only limited stud-
ies have assessed it in human glucose homeostasis. More-
over, there are scarce studies exploring the impact of diet
therapy on circulating miR-33b and miR-29a in obesity and
T2DM. We hypothesized that if diet can affect circulating
levels of microRNA, this interaction could explain the dif-
ferent pathogenesis of T2DM in various populations, in-
cluding in Iran, and may make possible the development
of new treatments to reduce the inheritability of T2DM.
2. Objectives
This study characterized the expression of miR-33b and
miR-29a in obese female patients with T2DM compared to
values from healthy, non-obese women. We also examined
the effects of a calorie-restricted diet on circulating miR-
33b and miR-29a levels in relationship to lipid and glucose
metabolism biomarkers in obese women with T2DM.
3. Methods
3.1. Study Population
The sample size was calculated by considering the pri-
mary outcomes of miR-33b (21) on the basis of Pocock’s
sample size formula with a power of 80% and a 95% con-
fidence interval (10 patients per study group), taking into
account a probable 30% loss of subjects. The study was
carried out in compliance with CONSORT guidelines, from
February 2014 to January 2015. The approved format of the
study was used after receiving an ethics code (92162) from
the ethics committee of Tabriz University of Medical Sci-
ences, as well as from the Iranian registry of clinical trials
(IRCT) (code no IRCT2014011416223N1).
At baseline, all patients were provided with a detailed
explanation of the study, and informed written consent
was signed by each participant. The subjects were selected
from 55 obese female volunteers with T2DM, based on the
study’s inclusion criteria, from the clinic of Emdadi hospi-
tal of Zanjan University of Medical Sciences, Zanjan, Iran.
The T2DM patients were all undergoing drug therapy with
Glucophage/glyburide. The participants consisted of 32
obese (BMI≥ 30 kg/m2) women aged 25 - 60 years with a
diagnosis of T2DM based on world health organization cri-
teria (22) for a minimum of two years, with a control group
of 10 healthy age-matched women with normal BMI (18 - 25
kg/m2). The diabetic subjects were sequentially numbered
from the beginning of the study and randomized with a
block size of 4 (1:1) by a statistician using RAS software (16
patients each in the treatment and control groups).
The exclusion criteria were pregnancy, lactation, di-
abetic ketoacidosis, acute presentation, heavy ketonuria,
history of major comorbidity (cardiovascular disease, liver
failure, renal disease, or malabsorption disorders), BMI of
≥ 45 kg/m2, any change in drug use throughout the study,
incomplete questionnaires, unwillingness to give blood
samples, the use of any special dietary plan (including veg-
etarian or calorie-restricted diets) within the previous year,
> 3 kg of weight change, the use of any type of dietary sup-
plement within the previous 3 months, history of hormone
therapy, insulin requirement, or a diagnosis of T1DM.
3.2. Dietary Intake
At the baseline, the validated 168-item semi-
quantitative food-frequency questionnaire (FFQ) (23)
was completed by a trained dietitian to determine the
habitual diet of each subject. Household kitchen scales
were delivered to the participants. Two-weekday and
one-weekend dietary records were filled out by each par-
ticipant. The portion sizes of the foods and beverages
consumed were converted into grams using household
measures (24), then coded and analyzed for energy con-
tent and other nutrients using the Iranian version of
Nutritionist IV software.
2 Iran Red Crescent Med J. 2017; 19(1):e37521.
Mohammadi S et al.
3.3. Diet Planning
For each subject in the treatment group, the person-
alized caloric intake was calculated by subtracting 700
Kcal from the obtained total energy expenditure, using
the standard equation for overweight and obese women
over 19 years of age, after considering the patient’s cur-
rent weight and physical activity coefficient (25). Physi-
cal activity levels and coefficients were determined using
the completed related questionnaires for each participant.
During the study, the diabetic patients continued their ha-
bitual physical activity without any changes. Personalized
calorie-restricted diets lasted 10 weeks and contained 17%,
53%, and 30% of energy as protein, carbohydrates, and fat,
respectively, which was designed based on the concepts
of low glycemic load and low glycemic index. Such diet
therapies are healthy therapeutic interventions that pro-
mote the health of patients with no side effects. During the
present study, the diabetic control group continued their
habitual diet. Medications were held constant during the
study, and the number of medications used in the two dia-
betic groups was adjusted by blocked randomization at the
baseline of the study. Three days of dietary records were
obtained at 5 and 10 weeks to estimate the subjects’ adher-
ence to the diet. All dietary measurements, planning, and
follow-up were performed by a trained dietitian.
3.4. Demographic, Clinical, and Anthropometric Measurements
Demographic, clinical, and anthropometric question-
naires were completed for all participants by a trained di-
etitian at baseline. Clinical and anthropometric question-
naires were collected again for the diabetic patients 5 and
10 weeks after the study began. The demographic infor-
mation included detailed medications, menopausal sta-
tus, stress quality and severity, quantity of sleep, education
level, job, physical activity, history of abortions or preg-
nancies, marital status, and a family history of obesity, di-
abetes, hypertension, or CVD. Waist circumference (WC) at
the point between the lowest rib and the superior border
of the right iliac crest, and hip circumference (HC) at the
widest point around the greater trochanters, were mea-
sured to the nearest 0.1 cm with the measuring tape di-
rectly on the individual’s skin (Seca, UK). The waist-to-hip
ratio (WHR) was calculated as WC/HC. Body weight (to the
nearest 0.1 kg) and visceral fat (%) were measured using a
calibrated and validated Omeron body-composition scale
(Seoul, Korea). Height was measured using a calibrated
portable stadiometer (Seca, UK) to the nearest 0.1 cm, with
the subject stretching to maximum height and the head
positioned in the Frankfort plane. BMI was calculated as
weight (kg)/height (m2). The same trained researcher took
all measurements, with the participant in the fasting state
and wearing soft indoor clothing without shoes.
3.5. Biochemical Measurements
At the baseline point in the study (for the diabetic pa-
tients and healthy participants) and after 10 weeks (for the
diabetic patients), 10-cc fasting blood samples were taken
in simple and 7.5% K3-EDTA tubes (Becton Dickinson Vacu-
tainer System, UK). The tubes were inverted five times, then
respectively centrifuged for 10 min at 13,000 x g (Eppen-
dorf 5702, US) and for a 40 minutes three-spin protocol
(1500 rpm for 30 min, 3000 rpm for 5 min, and 4500 rpm
for 5 minutes) (Eppendorf Vacufuge Plus, USA) to prevent
any contamination by cellular nucleic acids. The serum
and plasma samples were then stored at -80°C for further
processing. Plasma samples were stored in RNase-free mi-
crotubes while awaiting the microRNA assays.
Fasting blood sugar (FBS) and two-hour postprandial
blood sugar (2hPPBS) were measured with the GOD-PAP
method, serum triglycerides (TG) were measured with
GPO-PAP, and serum total cholesterol (TC) was measured by
enzymatic endpoint. All measurements were performed
using a Randox Laboratories kit (UK) (Hitachi 902, Roche
Diagnostics, USA) under the same conditions. The home-
ostasis model assessment (HOMA) was estimated for as-
sessing insulin resistance (HOMA-IR) and β-cell activity
(HOMA-β) in response to serum glucose concentrations be-
fore and after the study (26). Fasting and 2-hour postpran-
dial insulin levels were measured using enzyme-linked im-
munosorbent assay (ELISA) kits (Monobind Pharmaceuti-
cals, CA, USA; sensitivity 0.182 µIU/ ml; intra CV: 5.5%; in-
ter CV: 9.1%). All analyses were done in duplicate under the
same conditions in the central biotechnology laboratory
at Shahid Beheshti University of Medical Sciences, Tehran,
Iran, by a trained laboratory specialist.
3.6. Circulating RNA Extraction and cDNA Synthesis
For molecular assessments, plasma samples were col-
lected from the diabetic participants before and 10 weeks
after the study began. For the normal participants, sam-
ples were collected only at baseline. RNA extraction was
performed from 500 mL of each patient’s plasma sam-
ples stored in RNase-free microcentrifuge tubes according
to the QIAzol RNA extraction protocol (Qiagen, USA). Af-
ter confirming the integrity and quality of the RNA with
a spectrophotometer (Eppendorf, Hamburg, Germany),
DNase I treatment was performed following the manu-
facturer’s protocol (Sigma-Aldrich, USA). RNA was stored
at -80°C before use. Afterward, the extracted RNAs were
reverse-transcribed to cDNA using stem-loop reverse tran-
scriptase (RT) primers (for predicted miR-33b, miR-29a, and
SNORD U6) and ExpandTM Reverse Transcriptase (Roche Di-
agnostics GmbH Mannheim, Germany), according to the
manufacturer’s instructions. The cDNA was stored at -20°C
before use.
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3.7. Quantitative Real-Time RT-PCR
Triplicate real-time reverse-transcription polymerase
chain reactions (PCRs) were carried out for miR-33b and
miR-29a (and some unreported miRNAs) in 12.5µL PCR mix-
ture volumes consisting of Maxima® Probe qPCR Master
Mix (Fermentas, Lithuania), oligonucleotide primers and
probe, and 2 µL of cDNA. Amplification was carried out
in the LightCycler® rotor (Roche Diagnostics, Mannheim,
Germany) according to the manufacturer’s instructions.
Reaction setups were done manually. Cycle threshold (Ct)
values were calculated using LightCycler® software, ver-
sion 3.5,2001 (Roche Molecular Biochemicals, Mannheim,
Germany). The U6 gene was used as the reference gene
and underwent the aforementioned procedure. The non-
template control and RT-minus were used for the entirety
of the experiments. MIQE guidelines were used in all of the
manipulation steps. The fold changes of miR-33b and miR-
29a expressions (in the diabetic participants compared
with the normal controls before and after the interven-
tion) were calculated using the relative expression soft-
ware tool (REST®) as suggested by Pfaﬄ (27). RNA extrac-
tions and real-time RT-PCR were carried out in the molec-
ular cell biology laboratory at the stem cell technology re-
search department of Shahid Beheshti University of Medi-
cal Sciences, Tehran, Iran.
3.8. Statistical Analysis
Statistical analyses were performed using SPSS soft-
ware, version 15.0 (SPSS, Chicago, IL, USA). After testing
the normality and homogeneity of the variances using
the one-sample Kolmogorov-Smirnov descriptive analysis
and the Chi-square test, the quantitative variables were
matched with the Chi-square test. Variables were given
and analyzed in a base of log10-transformation where nec-
essary. Descriptive statistics were computed using mean
± standard deviation (SD) for continuous measurements.
The microRNA data (based on the advised principals for re-
porting the most accurate molecular measurements (28)
were expressed using mean ± standard error (SE). Alter-
ations in total energy and macronutrients were examined
with the repeated-measure analysis of variance (ANOVA).
The independent t-test or the Mann-Whitney U test and
the paired-T test or Wilcoxon’s test were used for group
comparisons. To adjust for the effects of multiple vari-
ables on the intervention, a univariate analysis of covari-
ance (ANCOVA) was used. Multiple linear regression tests
were carried out to assess the independent relationship of
the miRNA fold changes with other biochemical, anthro-
pometric, and nutritional factors in the study. For all of the
analyses, a two-sided P value of < 0.05 was deemed statis-
tically significant. All real-time PCR results were analyzed
using REST® 2009 software, and only the significant fold
changes were transferred to the SPSS file for further analy-
sis. Graphical procedures were performed using Microsoft
Excel 2007.
4. Results
4.1. Disposition, Demographic, and Clinical Characteristics of
Diabetic Patients and Healthy Participants
During the study, one patient each from the control
and treatment groups were lost to follow-up, while 30 di-
abetic women completed the study. Ten healthy women
also participated at the baseline of the study in order to
compare the expression levels of miRNA in obese patients
with the corresponding normal amounts (Figure 1). Pri-
marily, participants were frequency-matched for quantita-
tive variables, including menopausal status, stress, quality
and quantity of sleep, education level, job, physical activity,
history of abortion or pregnancy, marital status, and a fam-
ily history of obesity, diabetes, hypertension, or cardiovas-
cular disease (exact P > 0.05). There were no differences in
the number of healthy or diabetic participants with these
characteristics, or between the two diabetic groups. The
demographic and clinical characteristics of the healthy
participants and diabetic patients are shown in Tables 1
and 2.
4.2. Significant Reduction of Caloric and Carbohydrate Intake
in the Treatment Group
After testing the normal distribution, homogeneity,
and sphericity, the results of the repeated-measure ANOVA
test showed significant reductions of total energy intake
(from 1882.27± 149.94 to 1595.1± 110.58 Kcal/day; P = 0.001),
carbohydrate intake (from 231.48± 27.34 to 179.40± 33.08
g/day; P = 0.001), and fat intake (from 82.76 ± 10.87 to
72.88 ± 10.13 g/day; P = 0.019) during diet therapy in the
treatment group. The results did not show any significant
change in protein intake (from 52.87± 6.14 to 55.80± 9.30
g/day; P = 0.215). There was no significant change in energy
intake in the diabetic control group (from 1787.64± 318.59
to 1787.1± 322.05 Kcal/day; P = 0.045).
There was significant caloric reduction at the 5th and
10th weeks compared to before the study (-168.17± 57.17, P
= 0.013, and -286.752± 47.18, P < 0.001, respectively). There
were also significant reductions in dietary carbohydrates
at the 5th and 10th weeks of the diet therapy compared
to before the study (-33.26± 9.29, P = 0.004, and -52.08±
11.08, P < 0.001, respectively). We observed significant re-
ductions in dietary fat intake at the 10th week of diet ther-
apy compared to before the study and from the 5th to the
10th weeks (-9.87± 3.24, P = 0.011, and -5.38±2.38, P = 0.046,
respectively).
4 Iran Red Crescent Med J. 2017; 19(1):e37521.
Mohammadi S et al.
 
  
 
 
 
 
 
 
Enrollment  
Healthy Women with Normal Weight (n = 30)  Obese Women with T2DM (n = 55)  
 
Assessed for Eligibility (n = 10 Eligible 
Healthy Normal Weighted Women)  
Assessed for Eligibility (n = 32 
Obese Diabetic Women)  
 
Data Collection (Nutritional, Anthropometric, 
Biochemical, and qRT - PCR Measurement) 
and Analysis for all of 10 Healthy Women Randomized (n = 32)  
Allocated to Intervention (n = 16), Received Allocated 
Intervention (n = 16), Did Not Receive Allocated  
Intervention (n = 0)  
Allocated to Intervention (n = 16), Received Allocated 
Intervention (n = 0), Did Not Receive Allocated 
Intervention (n = 16)  
Follow-Up (Every Five Weeks)
 
Lost to Follow - Up, Due to Leg Fracture (n = 1)  
 
Lost to Follow - up Unwillingness to Continue  
Treatment (n = 1), Discontinued Intervention (n = 0)  
Analysis  
Analysed (n = 15), Excluded From Analysis (n = 0)  Analysed (n = 15), Excluded From Analysis (n = 0)  
Figure 1. The Present Study’s CONSORT Workflow
Table 1. Demographic and Clinical Characteristics of Participants at Baselinea
Healthy Participants (n = 10) Diabetic Patients (n = 30) P Valueb
Age, y 44.50± 5.79 49.60± 8.18 0.082
Weight kg 59.25± 6.21 81.95± 11.78 0.001c
BMI, kg/m2 22.35± 2.67 33.38± 4.16 0.001c
Total body fat, % 28.16± 5.40 45.84± 3.83 0.001c
Visceral fat, level 6.00± 0.81 10.60± 2.04 0.001c
SBP,mmHg 11.20± 1.03 13.74± 1.88 0.001c
DBP,mmHg 7.50± 0.52 9.19± 2.04 0.015d
FBS,mg/dL 73.80± 5.20 193.72± 70.44 0.001c
Logarithmof triglyceride,mg/dL 1.85± 0.13 2.22± 0.25 0.001c
Total cholesterol,mg/dL 170.80± 23.99 193.32± 33.22 0.061
Logarithmof fasting insulin,µU/mL -0.88± 0.13 1.02± 0.23 0.001c
Abbreviations: BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; FBS, fasting blood sugar; HC, hip circumference; MD, mean differences; SBP,
systolic blood pressure; WC, waist circumference.
aValues are expressed as mean± SD.
bP value from independent t-test.
cDifference is significant (P≤ 0.01).
dDifference is significant (P≤ 0.05).
4.3. Significantly Low Levels of Circulating MiR-33b and High
Levels of miR-29a in Diabetic Patients
To investigate the circulating levels of miR-33b and
miR-29a in the obese T2DM subjects, the initial circulating
miRNA levels at baseline were identified with RT-PCR as-
says and compared to those of healthy participants. Unlike
miR-33b levels, which were significantly lower in the obese
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Table 2. Demographic and Clinical Characteristics of Diabetic Patientsa
Control (n = 15) Treatment (n = 15) P Valueb
Baseline After the Study Baseline After the Study Baseline After the Study
Age, y 49.63± 9.57 49.28± 7.75 0.920
Diabetesmedications, n/d 3.15± 1.45 3.71± 1.63 0.764
Duration of diabetes, y 6.45± 4.27 8.00± 4.64 0.401
Weight, kg 82.80± 13.45 82.60± 14.18 81.28± 10.76 79.94± 11.65c 0.757 0.626
BMI, kg/m2 34.57± 5.62 34.45± 5.97 32.45± 2.34 31.86± 2.40c 0.212 0.180
Visceral fat, level 11.09± 2.66 11.54± 2.84 10.33± 1.43 9.83± 1.46d 0.296 0.727
WC, cm 109.97± 14.09 111.50± 15.05 108.36± 8.61 104.17± 7.99c 0.727 0.154
HC, cm 114.91± 12.27 115.41± 12.05 113.08± 9.35 109.96± 8.99d 0.676 0.230
WHR 0.95± 0.06 0.96± 0.07 0.96± 0.05 0.94± 0.02 0.909 0.459
FBS,mg/dL 182.64± 69.40 172.82± 64.68 202.43± 72.60 148.50± 72.05c 0.497 0.417
2hPPBS,mg/dL 254.91± 119.39 257.36± 100.00 267.14± 88.92 192.92± 77.90c 0.771 0.098
Cholesterol,mg/dL 178.55± 36.21 190.36± 48.92 207.20± 24.68 203.00± 25.23 0.046 0.427
L-trigyceridemg/dL 2.24± 0.23 2.28± 0.18 2.22± 0.27 2.19± 0.24 0.946 0.379
L-fasting insulin,µU/mL 1.09± 0.28 0.97± 0.25 0.97± 0.17 0.94± 0.23 0.222 0.651
L-HOMA-IR 0.72± 0.34 0.57± 0.25 0.64± 0.28 0.46± 0.40d 0.384 0.225
HOMA-B, % -30.91± 19.62 -35.81± 18.59 - 44.13± 6.21 - 38.60± 7.75d 0.026d 0.638
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; HC, hip circumference; FBS, fasting blood sugar; HOMA-IR or β, homeostatic model assessment
insulin resistance or β-cell function; L, logarithm; SBP, systolic blood pressure; WC, waist circumference; WHR, waist-to-hip ratio; 2hPPSB, 2-hour postprandial blood
sugar.
aValues are expressed as mean± SD.
bP value from independent t-test for non-logarithmic and exact p value from the Mann-Whitney U test for logarithmic values.
cP < 0.01.
dP < 0.05.for paired comparisons before versus after study (paired t-test for non-logarithmic and exact P value Wilcoxon’s test for logarithmic values). (These data have
been reported in our unpublished recent manuscript (29)).
T2DM patients, circulating levels of miR-29a were higher in
these patients than in the healthy control group (Figure 2).
4.4. Circulating Levels of miR-33b Increased Significantly in Di-
abetic Patients During Diet Therapy
In order to evaluate the effects of a calorie-restricted
diet on the expressions of miR-33b and miR-29a in the di-
abetic patients, circulating levels of these microRNAs were
detected at baseline and at the 10th week of the study with
RT-PCR assays. Interestingly, compared with those of the
healthy normal-weight women, circulating levels of miR-
33b increased significantly in the treatment group, up to
normal levels (Figure 3). However, no significant change
was observed in the circulating levels of miR-29a after the
treatment (data not shown).
4.5. Independent Significant Negative Relationship of miR-33b
Fold Change With Caloric Restriction and 2hPPBS in the Treat-
ment Group
As reported in our previous manuscript (29), the re-
sults of the ANCOVA test showed that diet therapy indepen-
dently improved most of the anthropometric measures (P
< 0.05), FBS (P = 0.024, MD -37.47, 95% CI: -69.37 to -5.57
mg/dL), 2hPPBS (P = 0.007, -72,86; -123.34 to -22.3 mg/dL),
and serum total cholesterol (P = 0.005; -28,10; -46.48 to
-9.72 mg/dL) in the treatment group. In order to sepa-
rate the independent effects of macronutrients on miRNA
fold changes and the relationship of miRNA with glucose
and lipid metabolism biomarkers, we assessed the cor-
relations between the fold changes of miR-33b and miR-
29a and the significant changes of anthropometric, bio-
chemical, and dietary factors during the study in both dia-
betic groups, and reported the significant relationships. As
shown in Table 3, unlike the results for miR-29a, we found
important independent negative correlations of miR-33b
fold changes with caloric intake and levels of 2hPPBS in
the treatment group after adjusting all other measured in-
dices in this study.
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Figure 2. Fold Change of miR-33b and miR-29a in T2DM Patients (n = 30) Compared
With Normal Women (n = 10) at Baseline, From the Results of Quantitative RT-PCR
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Values are expressed as mean± SE (standard error). *Fold change is significant (P≤
0.05).
5. Discussion
The rising prevalence of T2DM and its complications,
in tandem with obesity and nutritional factors, indicate
the regulatory network among the epigenetic factors, in-
cluding miRNAs, obesity, and nutrition (15, 30). Dysregula-
tion of miRNA, as the post-transcriptional modification of
target genes involved in glucose and lipid metabolic path-
ways, leads to the pathology of diabetes and its complica-
tions (15).
In this study, we demonstrated significantly decreased
energy intake, total dietary fat intake, and carbohydrate in-
take in obese women with T2DM under the diet therapy.
Based on the evidence from this nutritional analysis, the
mean caloric restriction in the treatment group was ap-
proximately 230 Kcal/day during the study. Therefore, the
adherence of the patients in this study to the treatment
diet was approximately 35%. It has been observed that di-
abetic patients’ average adherence to therapeutic proce-
dures in developed countries is < 50% (31).
To investigate the effects of diet therapy on post-
transcriptional epigenetic modulations of glucose and
lipid metabolic pathways, we examined the impact of a
calorie-restricted diet on circulating levels of miR-33b and
miR-29a in obese women with T2DM. Initially, the quanti-
tative RT-PCR assays indicated that the circulating levels of
miR-33b and miR-29a were lower (-143%) and higher (40%),
respectively, in obese T2DM patients compared to healthy
normal-weight women (Figure 2). We found that a diet that
controlled calories from total fat and carbohydrate intake
can mediate a significant upregulation of miR-33b (~ 97%),
toward normal circulating levels, in obese T2DM women
(Figure 3). Interestingly, a significant negative correlation
was identified between the fold change of miR-33b and the
amount of restricted calories in the treatment group (Ta-
ble 3). This novel observation introduces diet therapy as an
important epigenetic modulator in the regulation of miR-
33b expression to normal levels.
MiR-33b is encoded in humans and large mammals,
but not in rodents, with a two-nucleotide difference from
miR-33a. While the same target activities have already
been suggested for miR-33a and miR-33b, they have differ-
ent patterns of evolutionary conservation (13, 20). Stud-
ies exploring the effects of human miR-33b on glucose and
lipid metabolism pathways are scarce. Considering the
significant miR-33b downregulation (-143%) in the obese
T2DM patients and a recent report on the suppressed ex-
pression of SREBP-1c in the hypertrophic adipose tissues
of ob/ob mice (32), we can propose that insulin resis-
tance in obesity may cause downregulation of SREBP-1c
and a consequential downregulation of miR-33b. Induc-
tion of miR-33b expression in patients on diet therapies
has been demonstrated along with improved glucose and
lipid metabolism. As shown in Table 3, we demonstrated a
significant correlation between increased circulating miR-
33b and decreased 2hPPBS in T2DM patients under the diet
therapy. This is in agreement with a previous study that
reported the inverse effect of miR-33b on glycemic control
in hepatocytes through the inhibition of miR-33b’s targets,
including pyruvate carboxykinase (PCK1) and glucose-6-
phosphatase (G6PC), two key regulatory enzymes of hep-
atic gluconeogenesis (19). MiR-33b also regulates choles-
terol homeostasis by targeting key transcriptional regu-
lators of lipid metabolism, including steroid receptor co-
activator 1 (SRC1), steroid receptor co-activator 3 (SRC3), nu-
clear transcription factor Y subunit gamma (NFYC), and nu-
clear receptor-interacting protein 140 (RIP140) (19). Also,
we did not see any significant correlation between miR-33b
fold changes and lipid metabolism biomarkers in obese
women with T2DM.
To further evaluate the effects of a calorie-restricted
diet on the expression of the involved miRNAs in metabolic
pathways, we also detected circulating levels of miR-29a
before and after the diet therapy in the diabetic patients.
An increased circulating level of miR-29a (40%) was ob-
served in the obese T2DM patients compared to healthy
normal-weight women (Figure 2). This finding was in line
with new evidence (18, 33) but in contrast to an animal
study (34). However, our study did not show any marked
effect of calorie-controlled diet therapy on miR-29a expres-
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Figure 3. Fold Change of miR-33b in T2DM Patients During the Study Compared With Healthy Women, From the Results of Quantitative RT-PCR
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Values are expressed as mean± SE (standard error). (A) Diabetic control group (n = 15) vs. healthy women (n = 10) (exact P value from Wilcoxon analysis = 0.613). (B) Diabetic
treatment group (n = 15) vs. healthy women (n = 10) (exact P value from Wilcoxon analysis = 0.011).
Table 3. Relationship Between miR-33b Fold Change and Changes in Calorie Intake During the Study in the Treatment Group
Fold Change ofmiR-33b
βa 95% CIa P Valuea
Calorie intake -0.619 -0.004 to -0.001 0.022b
2hPPBS -0.603 -0.009 to -0.001 0.035b
Abbreviation: 2hPPBS, 2-hour post-prandial blood sugar.
aResults of multiple linear regression analysis, adjusted for anthropometric, biochemical, and dietary indices in the study.
bCorrelation is significant at the 0.05 level (2-tailed).
sion. Previous reports have shown the roles of the miR-29
family in the reduction of glucose production, decreased
glucose tolerance, and increased insulin synaptic exocy-
tose in human INS-1E β cells (17, 35) and in animal mod-
els (18). These findings suggest, to some extent, that there
is a compensatory role of miR-29a in offsetting high cir-
culating glucose and insulin resistance in obese diabetic
humans. Considering the pathophysiology of T2DM (36),
since miR-29a affects the upstream genes of insulin secre-
tion from the β-cells (17, 18), we propose that more time is
required to assess the probable results of diet therapies on
the expression of miR-29a in obese T2DM subjects.
Our findings introduce moderate restricted caloric in-
take from fat and carbohydrate as an epigenetic modula-
tor of miR-33b expression in the treatment of obesity and
diabetic complications. We suggest that a balanced ex-
pression of miR-33b and miR-29a is necessary to achieve
the ideal regulation of genes involved in glucose and lipid
metabolism and in complications of diabetes in obese
T2DM patients.
With regard to conducting comprehensive research
and identifying probable independent relationships, one
advantage of the present study is that it is one of the few
molecular human studies that have considered the differ-
ent nutritional, anthropometric, biochemical, and molec-
ular aspects of glucose and lipid metabolism in one frame-
work, using participants in a similar geographic region
with matched demographic characteristics. Dietary inter-
ventional studies on human miRNA levels are in their in-
fancy, and further studies are necessary in order to obtain
detailed knowledge about the therapeutic effects of diet
protocols on miR-29a levels in obese diabetic patients. Be-
cause of the need to keep the patients’ medications con-
stant throughout the study, we could not continue the in-
tervention for more than 10 weeks under stable conditions.
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